Lung NGS Fusion Panel (Complete or Limited)

The Lung NGS Fusion Panel (Complete or Limited) is an RNA-based next-generation sequencing panel that detects translocations and fusions of the genes ALK, MET including MET Exon 14 skipping, NTRK1, NTRK2, NTRK3, NRG1, RET and ROS1 with known and novel fusion partners. Examples of some of the published fusions detectable in this test include EML4-ALK, KIF5B-ALK, NPM1-ALK, CD74-NTRK1, MPRIP-NTRK1, TPM3-NTRK1, TRIM24-NTRK2, PAN3-NTRK2, ETV6-NTRK3, CCD6-RET (aka RET-PTC1), KIF5B-RET, NCOA4-RET (aka RET-PTC3), CD74-ROS1, SLC34A2-ROS1, and TPM3-ROS1. Lung Complete NGS Fusion Panel includes all genes listed above. Clients can opt out of ALK and ROS1 testing to receive the Lung Limited NGS Fusion Panel report. This test may be used to select patients for the following FDA-approved therapies:  ALK- ALECENSA® (alectinib), XALKORI® (crizotinib), ZYKADIA (ceritinib), ALUNBRIG® (brigatinib), LORBRENA® (lorlatinib) MET Exon 14- TABRECTA (capmatinib) NTRK- ROZLYTREK® (entrectinib), VITRAKVI® (larotrectinib) RET- GAVRETO (pralsetinib), RETEVMO (selpercatinib) ROS- XALKORI® (crizotinib), ROZLYTREK® (entrectinib)